ClinicalTrials.gg
CompletedNCT05910450SCALP1Updated Jun 8, 2026

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

A Phase 3 interventional study of Clascoterone 5% solution and Vehicle solution in Alopecia, Androgenetic, sponsored by Cassiopea SpA. Completed at 24 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Cassiopea SpA · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
703
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
5th of 203
703 · median 40
Started
2023
with 17 others
Phase 3
14 of 216
2 open now
Registered
154th of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 5th largest by enrollment of the 203 interventional ones that give a count, is one of 18 that started in 2023, is one of 14 in phase 3, and was the 154th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.

Within this study, the Clascoterone solution will be compared to a placebo.

The study has 2 parts:

Part 1 will see if Clascoterone solution is effective and safe compared to a placebo when applied twice daily for up to 6 months.

Part 2 will see the long-term safety and efficacy of the Clascoterone solution compared to placebo for additional 6 months in subjects defined as ''responders'' in Part 1. A responder is defined as someone who have responded to the study drug, based on research data.

Part 1 of the study is double-blind, meaning that neither the subject nor the study doctor knows which treatment subject is receiving. Part 2 of the study is single-blind and only the study doctor doing the study knows which treatment subject is receiving.

Part 1 of the study will start with baseline visit during which subjects will be randomly assigned (by chance) in ratio 2:1 to apply either Clascoterone or placebo solution to their balding areas of the scalp. Subjects will have 5 clinic visits and 2 follow-up phone calls during 6 months of Part 1 duration. Subjects identified as Part 1 responders at Month 6 visit will be again randomly assigned in ratio 2:1 to receive either study drug or placebo.

Part 2 of the study will consist of 2 additional clinic visits and treatment will last for further 6 months.

Each subject will have also an end of study visit one month after the study drug treatment has been completed or discontinued (it will be one month after end of Part 1 for not responder subjects).

For those subjects who complete the whole study (Part 1 and Part 2), the total duration of the study will be about 14 months, with 12 months of treatment with a total of eight clinic visits and two phone calls.

Subjects taking part in this study will have the medical tests or procedures described below.

  • They will be asked about their previous medical history and current medications.
  • A brief physical examination will be performed.
  • Vital signs, weight and height will be measured.
  • Electrocardiograms will be performed.
  • Subject's scalp will be checked for any signs of irritation.
  • Two different types of photos will be taken during this study: "global photos", i.e. general photos of the subject's scalp and "macro photos", i.e. close up photos of a region of the subject's scalp. Global photos will be taken to help the subject and the study doctor to assess whether there has been a change in subject's hair growth. Macro photos will be used to count the number of hairs in a region of the subject's scalp and measure other properties of the hair (hair width and hair darkness).
  • Blood draws and urine sample collection for safety laboratory tests.
  • Subject will be asked to complete, on site, the following two questionnaires:

    • Cosmetic Evaluation - a couple of cosmetic questions on acceptability and how easy the study drug is to use.
    • Male Androgenetic Alopecia Questionnaire - some questions about subject's hair assessment.

Eligible subjects will be given a supply of the study drug and shown how to use and store it. The first study drug dose will be applied at the clinic under the supervision of the study staff. Subjects will be instructed to apply about 1.5 ml of study drug with a dropper to the balding areas of the scalp on the vertex and the temples twice daily, once in the morning and once in the evening.

Subjects will be asked to bring back all used containers of study drug and all unused study drug to each study visit. Subjects will also be given a diary, shown what things have to be recorded on it and asked to bring back the completed diary to the study center at each visit.

03

Conditions studied

  • Alopecia, Androgenetic

Browse trials for

Keywords

  • Alopecia
  • Androgenetic
  • Clascoterone solution
  • Phase 3
  • Randomized
  • Double-blind
  • Vehicle-controlled
  • AGA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject can participate in this clinical study if all the following criteria are met:

  1. Subject who is male ≥18 years old.
  2. Subject who has provided written .
  3. Subject who has mild to moderate AGA in temple and vertex region, rating III vertex to V on the Modified Norwood-Hamilton Scale (i.e., III vertex [IIIv], IV, or V), with a history of ongoing hair loss.
  4. Subject who is willing to maintain the same hairstyle, hair length and hair color throughout the study.
  5. Subject who is willing to comply with study instructions at home and return to the clinic for required visits.
  6. Subject who agrees to continue his shampoo frequency and other general hair care products and regimen for the entire study.
  7. Subject who agrees to maintain same dietary and supplement pattern.
  8. Subjects who are sexually active with a female partner and are not surgically sterile (vasectomy performed at least 6 months prior to treatment) must agree to use an acceptable form of as described in the informed consent form. For subjects, adequate forms of contraception include condom and spermicide in combination with other forms of female contraception. For females, an acceptable method (Pearl Index \<1%) would be to agree to use implants, injectables, combined oral contraceptives, some intrauterine devices, or be (defined as amenorrhea greater than 12 consecutive months in women 50 years of age or older), be surgically sterile (hysterectomy, bilateral tubal ligation [at least 6 months prior], or bilateral oophorectomy).

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to participate in the study:

  1. Subject who has any dermatological disorders of the scalp in the target region with the possibility of interfering with the application of the IMP or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis, scars, or scalp atrophy.
  2. Subject who has any skin pathology or condition that, in the investigator's opinion, could interfere with the evaluation of the IMP or requires use of interfering topical, systemic (e.g., uncontrolled thyroid disease, certain genetic disorders that involve hair growth or patterns), or surgical therapy.
  3. Subject who has current or recent history (within 6 months) of hair weaves, non-breathable wigs, or hair bonding.
  4. Subject who had scalp hair transplants at any time.
  5. Subject with a history of active hair loss due to diffuse telogen effluvium, alopecia areata, scarring alopecia, trichotillomania, or conditions/diseases other than AGA.
  6. Subject who has a current or recent history (within 6 months) of severe dietary or weight changes or has a history of eating disorder(s), any history of bariatric surgery (gastric bypass, gastric sleeve, stomach stapling); macro- or micro-nutrient deficiencies within the last 6 months (i.e.: iron deficiency, protein deficiency confirmed by lab testing) and/or any current diagnosis of malabsorptive disease (i.e.: Celiac, Irritable Bowel disease etc.).
  7. Subject who has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this study, including 12-lead (ECG) findings during the screening period.
  8. Subject is currently enrolled in an drug or device study.
  9. Subject who has used an investigational drug or investigational device treatment within 30 days or 5 half-lives whichever is longer prior to Visit 2/Baseline.
  10. Subject who is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
  11. Subject who has used or is suspected, in the investigator's opinion, to be using anabolic steroids.
  12. Subject who may be unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, and/or subjects who will be unable to return for scheduled follow-up visits.
  13. Subject who has a known or previous allergic reaction to any of the active or inactive ingredients in the IMPs or tattoo ink.
  14. Subject who has used any of the following topical preparations or procedures on the scalp:

    1. Topical scalp treatments for hair growth including minoxidil, Aminexil, hormone therapy, anti-androgens, or other agents that are known to affect hair growth within 12 weeks of Visit 2/Baseline.
    2. Topical scalp over-the-counter (OTC) or cosmetic treatments known or reasonably believed to affect hair growth (e.g., brands such as Maxilene, Nioxin, Foltene, etc.) or hair health or hair growth products with saw palmetto, copper, etc. within 2 weeks of Visit 2/Baseline.
    3. Topical scalp treatments that may have ancillary effect on hair growth including, but not limited to, , pimecrolimus, tacrolimus, and retinoids within 4 weeks of Visit 2/Baseline.
    4. Scalp procedures (surgical, laser, light, or energy treatments, micro-needling, etc.) within 6 months of Visit 2/Baseline.
    5. rich plasma (PRP) procedure on the scalp within 6 months of Visit 2/Baseline.
  15. Subject who has used one or more of the following systemic medications or procedures:

    1. Beta blockers, cimetidine, diazoxide, or corticosteroids (including intramuscular and intralesional injections) within 12 weeks of Visit 2/Baseline. Inhaled, intranasal, or ocular corticosteroids are allowed if use is stable [defined as doses and frequency unchanged for at least 4 weeks prior to Visit 2/Baseline].
    2. Retinoid, isotretinoin, vitamin A intake above 10,000 IU per day, or cyclosporine therapy within 6 months of Visit 2/Baseline.
    3. Any 5 alpha reductase medications (i.e.: Finasteride [Propecia®, etc.], Dutasteride or similar products within 6 months of Visit 2/Baseline.
    4. Chemotherapy or cytotoxic agents at any time.
    5. Radiation of the scalp at any time point.
    6. Other systemic therapy, which in the opinion of the investigator, may materially affect the subject's hair or hair growth, including, but not limited to, spironolactone, vitamin or homeopathy supplement hair growth or hair health products or other steroid hormones (in any form), including anabolic steroids during the 3 months prior to baseline or during the study.
  16. Subject who has been previously enrolled in any study with Clascoterone (former CB 03 01).
  17. Subject who is an employee or direct relative of an employee of the contract research organization (CRO), the study site, or the Sponsor.
  18. Subject who is institutionalized because of legal or regulatory order.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
703 participants (actual)

Study arms

  • Experimental
    Clascoterone Part 1 and Part 2

    Subjects treated for 12 months with Clascoterone 5% solution (both in double-blind Part 1 and in the single-blind Part 2 of the study)

    Drug: Clascoterone 5% solution

  • Other
    Clascoterone Part 1 + Vehicle Part 2

    Subjects treated for the first 6 months Part 1 in double-blind with Clascoterone 5% solution followed by 6 months Part 2 in the single-blind label with Vehicle

    Drug: Clascoterone 5% solution · Drug: Vehicle solution

  • Other
    Vehicle Part 1 + Clascoterone Part 2

    Subjects treated for the first 6 months Part 1 in double-blind with Vehicle followed by 6 months Part 2 in the single-blind label with Clascoterone 5% solution.

    Drug: Clascoterone 5% solution · Drug: Vehicle solution

  • Placebo comparator
    Vehicle Part 1 and Part 2

    Subjects treated for 12 months with Vehicle (both in double-blind Part 1 and in the single-blind Part 2 of the study)

    Drug: Vehicle solution

Interventions

  • Topical application of 1.5 ml of clascoterone solution 5%, twice a day, to balding areas of the scalp (vertex and temples)

    Also known as: CB-03-01 5% solution

  • DrugVehicle solution

    Topical application of 1.5 ml of vehicle, twice a day, to balding areas of the scalp (vertex and temples)

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Changes in non-vellus Total Area Hair Count (TAHC)

    Changes from Pivotal Part 1 Baseline in non-vellus Total Area Hair Count (TAHC) at Month 6.

    Time frame: 6 months

  2. Subject's assessment of own hair coverage

    MAA-PRO item 8, a hair coverage-specific PGI-C, as the co-primary endpoint. The clinically meaningful change (threshold) is defined as a response of "1", "2", or "3". Note that the item 2 responder threshold was used as a criterion for subjects to qualify for Part 2 enrollment.

    Time frame: 6 months

Secondary outcomes

  1. Changes in non-vellus TAHC

    Changes from Pivotal Part 1 Baseline in non-vellus TAHC at Month 3.

    Time frame: 3 months

  2. Changes in subject's assessment of satisfaction score

    Changes in MAA-PRO SI (Male Androgenetic Alopecia-Patient Reported Outcomes Satisfaction Index) single treatment satisfaction item (item 15) score (i.e. question: "How satisfied are you with the study treatment?") at Month 6, with a minimum value of "Very dissatisfied" and a maximum value of "Very satisfied."

    Time frame: 6 months

07

Study locations

24 sites
  • The Petrus Center for Aesthetic Surgery and Hair Transplantation
    North Little Rock, Arkansas 72116, United States
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Mayo Clinic, Department of Dermatology
    Jacksonville, Florida 32224, United States
  • University of Miami
    Miami, Florida 33125, United States
  • DelRicht Research
    Baton Rouge, Louisiana 70809, United States
  • DelRicht Research
    New Orleans, Louisiana 70115, United States
  • Henry Ford Health
    Detroit, Michigan 48202, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • JDR Dermatology Research
    Las Vegas, Nevada 89148, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Diane S. Berson MD, PLLC
    New York, New York 10022, United States
  • Derm Research Center of New York, Inc.
    Stony Brook, New York 11790, United States
  • On Site Clinical Solutions
    Charlotte, North Carolina 28277, United States
  • DermResearch
    Austin, Texas 78759, United States
  • DelRicht Research
    Frisco, Texas 75034, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • LTD Health
    Batumi, 6000, Georgia
  • JSC Curatio
    Tbilisi, 0114, Georgia
  • Kanveni National Center of Dermatology and Venerology
    Tbilisi, 0159, Georgia
  • Tbilisi Cancer Center
    Tbilisi, 0159, Georgia
  • Aversi Clinic
    Tbilisi, 0160, Georgia
  • Medi Club
    Tbilisi, 0160, Georgia
  • David Abuladze Georgian-Italian Clinic
    Tbilisi, 0179, Georgia
  • LTD "Medinvestment"
    Tbilisi, 0186, Georgia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jan 2026, 31 months.

Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 18, 2023
StartActual
Jun 21, 2023
Primary completionActual
Jan 26, 2026
CompletionActual
Jan 26, 2026
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05910450
Lead sponsor
Cassiopea SpA
Collaborators
Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Jun 21, 2023
Primary completion
Jan 26, 2026
Completion
Jan 26, 2026
Last update
Jun 8, 2026

Study contacts

Alessandro Mazzetti, M.D.
study director · Cassiopea SpA

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clascoterone

Start the discussion